T. Rowe Price Associates
RVMD icon

T. Rowe Price Associates’s Revolution Medicines RVMD Stock Holding History

T. Rowe Price Associates’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448M Sell
2,390,303
-841,910
-26% -$123M 0.04% 301
2026
Q1 		$314M Sell
3,232,213
-172,504
-5% -$17.4M 0.04% 351
2025
Q4 		$271M Sell
3,404,717
-468,989
-12% -$30.8M 0.03% 379
2025
Q3 		$181M Sell
3,873,706
-828,256
-18% -$32.4M 0.02% 483
2025
Q2 		$173M Sell
4,701,962
-897,680
-16% -$34.5M 0.02% 465
2025
Q1 		$198M Sell
5,599,642
-266,320
-5% -$10.8M 0.02% 420
2024
Q4 		$257M Buy
5,865,962
+552,657
+10% +$27.9M 0.03% 376
2024
Q3 		$241M Buy
5,313,305
+96,646
+2% +$4.21M 0.03% 397
2024
Q2 		$202M Buy
5,216,659
+402,349
+8% +$15M 0.02% 415
2024
Q1 		$155M Buy
4,814,310
+177,957
+4% +$5.27M 0.02% 468
2023
Q4 		$133M Sell
4,636,353
-458,353
-9% -$11M 0.02% 495
2023
Q3 		$141M Buy
5,094,706
+75,941
+2% +$2.25M 0.02% 451
2023
Q2 		$134M Sell
5,018,765
-16,414
-0.3% -$403K 0.02% 474
2023
Q1 		$109M Buy
5,035,179
+1,355,137
+37% +$33.4M 0.02% 493
2022
Q4 		$87.7M Buy
3,680,042
+27,414
+0.8% +$583K 0.01% 519
2022
Q3 		$72M Buy
3,652,628
+1,414,774
+63% +$31.1M 0.01% 554
2022
Q2 		$43.6M Sell
2,237,854
-61,962
-3% -$1.21M 0.01% 920
2022
Q1 		$58.7M Buy
2,299,816
+1,244,045
+118% +$27.1M 0.01% 917
2021
Q4 		$26.6M Buy
1,055,771
+35,925
+4% +$1.01M ﹤0.01% 1209
2021
Q3 		$28.1M Buy
1,019,846
+1,001,922
+5,590% +$29.2M ﹤0.01% 1198
2021
Q2 		$569K Buy
17,924
+2,049
+13% +$71.5K ﹤0.01% 2332
2021
Q1 		$728K Sell
15,875
-76,945
-83% -$3.45M ﹤0.01% 2195
2020
Q4 		$3.67M Buy
+92,820
New +$3.67M ﹤0.01% 1487
2020
Q3 		– Sell
-133,371
Closed -$4.21M – 2621
2020
Q2 		$4.21M Buy
133,371
+37,939
+40% +$1.19M ﹤0.01% 1402
2020
Q1 		$2.09M Buy
+95,432
New +$2.64M ﹤0.01% 1489

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates's RVMD Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Revolution Medicines (RVMD) stake by 26% in Q2 2026, selling an estimated $123M and leaving 2,390,303 shares worth $448M. The position accounts for 0.04% of the portfolio, ranked #301.

T. Rowe Price Associates first reported a position in RVMD in Q1 2020 and has held it in 25 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • T. Rowe Price Associates held 2,390,303 shares of Revolution Medicines worth $448M as of Q2 2026.
  • T. Rowe Price Associates sold 841,910 Revolution Medicines shares in Q2 2026, an estimated $123M.
  • Revolution Medicines made up 0.04% of T. Rowe Price Associates's portfolio in Q2 2026, its #301 holding.
  • T. Rowe Price Associates first reported a position in Revolution Medicines in Q1 2020 and has held it in 25 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.